4CPS-017 Misuse of novel oral anticoagulants in hospital settings Article Swipe
Konstantinos Ioannidis
,
I Scarlatinis
,
Apostolos Papachristos
,
Xenia Madia
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1136/ejhpharm-2018-eahpconf.108
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1136/ejhpharm-2018-eahpconf.108
Background In the past few years, the development of three novel oral anticoagulants (NOACs), which directly target thrombin or factor Xa, has brought a remarkable change in the clinical practice of anticoagulation therapy. Although they constitute an attractive alternative option to warfarin and heparin, the appropriate use of these agents is essential in order to maximise their effect and avoid adverse events. Purpose The aim of the present study is to investigate two clinical pharmacists’ interventions regarding NOACs’ usage in a private hospital. Material and methods A prospective study was conducted at a Private General Hospital from 1 January 2016 to 31 December 2016. NOACs were administered in different doses according to indication, bodyweight, age and comorbidities. During the study period, the clinical pharmacists documented all cases where NOACs were prescribed. Data were analysed so as to reveal potential medication errors. Results Totally, 370 cases of NOACs’ administration were recorded, of which, 42 (11.4%) included a medication error. Among these mistakes, 28 (66.7%) were related to erroneously calculated NOACs’ dosage based on renal function, eight (19%) to drug-drug interactions and six (14.3%) to concurrent active cancer. Apixaban was the most frequent NOAC to be erroneously administered (13 of 76 cases, 17.1%), followed by rivaroxaban (28 of 257 cases, 10.9%) and dabigatran (one of 37 cases. 2.7%). Conclusion No matter how advantageous NOACs seem to be, they are accompanied by several risks which are more likely to happen if these agents are not appropriately used. Both the efficacy and bleeding risk depend on patient variables, such as renal function, age, weight and concomitant medication, whereas, due to their recent authorisation, there is insufficient experience on their benefit-to-risk ratio in special cases, such as cancer, obesity or childhood. The present study showed that, in our hospital, a significant amount of patients (11.4%) received NOACs in a way that contradicts the product label guidelines. The necessity to take patients’ medical history and NOACs’ pharmacological characteristics into account was highlighted, along with the potential contribution of a drug-handling expert, such as a clinical pharmacist. No conflict of interest
Related Topics
Concepts
Apixaban
Dabigatran
Rivaroxaban
Medicine
Intensive care medicine
Warfarin
Polypharmacy
Psychological intervention
Emergency medicine
Atrial fibrillation
Internal medicine
Psychiatry
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1136/ejhpharm-2018-eahpconf.108
- OA Status
- green
- Cited By
- 1
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2806797669
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2806797669Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1136/ejhpharm-2018-eahpconf.108Digital Object Identifier
- Title
-
4CPS-017 Misuse of novel oral anticoagulants in hospital settingsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-03-01Full publication date if available
- Authors
-
Konstantinos Ioannidis, I Scarlatinis, Apostolos Papachristos, Xenia MadiaList of authors in order
- Landing page
-
https://doi.org/10.1136/ejhpharm-2018-eahpconf.108Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/7535373Direct OA link when available
- Concepts
-
Apixaban, Dabigatran, Rivaroxaban, Medicine, Intensive care medicine, Warfarin, Polypharmacy, Psychological intervention, Emergency medicine, Atrial fibrillation, Internal medicine, PsychiatryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2018: 1Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2806797669 |
|---|---|
| doi | https://doi.org/10.1136/ejhpharm-2018-eahpconf.108 |
| ids.doi | https://doi.org/10.1136/ejhpharm-2018-eahpconf.108 |
| ids.mag | 2806797669 |
| ids.openalex | https://openalex.org/W2806797669 |
| fwci | 10.24999954 |
| type | article |
| title | 4CPS-017 Misuse of novel oral anticoagulants in hospital settings |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | A49 |
| biblio.first_page | A49.1 |
| topics[0].id | https://openalex.org/T10496 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9125999808311462 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2717 |
| topics[0].subfield.display_name | Geriatrics and Gerontology |
| topics[0].display_name | Pharmaceutical Practices and Patient Outcomes |
| topics[1].id | https://openalex.org/T10065 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9107999801635742 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2705 |
| topics[1].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[1].display_name | Atrial Fibrillation Management and Outcomes |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780638905 |
| concepts[0].level | 5 |
| concepts[0].score | 0.8900240659713745 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q414462 |
| concepts[0].display_name | Apixaban |
| concepts[1].id | https://openalex.org/C2778810321 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8424474000930786 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q419345 |
| concepts[1].display_name | Dabigatran |
| concepts[2].id | https://openalex.org/C2778661090 |
| concepts[2].level | 4 |
| concepts[2].score | 0.8296358585357666 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q420262 |
| concepts[2].display_name | Rivaroxaban |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.8181043863296509 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C177713679 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5364568829536438 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[4].display_name | Intensive care medicine |
| concepts[5].id | https://openalex.org/C2776301958 |
| concepts[5].level | 3 |
| concepts[5].score | 0.4831813871860504 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q407431 |
| concepts[5].display_name | Warfarin |
| concepts[6].id | https://openalex.org/C36434225 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4273143410682678 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1895998 |
| concepts[6].display_name | Polypharmacy |
| concepts[7].id | https://openalex.org/C27415008 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4142628014087677 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q7256382 |
| concepts[7].display_name | Psychological intervention |
| concepts[8].id | https://openalex.org/C194828623 |
| concepts[8].level | 1 |
| concepts[8].score | 0.34862154722213745 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2861470 |
| concepts[8].display_name | Emergency medicine |
| concepts[9].id | https://openalex.org/C2779161974 |
| concepts[9].level | 2 |
| concepts[9].score | 0.3006132245063782 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q815819 |
| concepts[9].display_name | Atrial fibrillation |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.2486635446548462 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C118552586 |
| concepts[11].level | 1 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7867 |
| concepts[11].display_name | Psychiatry |
| keywords[0].id | https://openalex.org/keywords/apixaban |
| keywords[0].score | 0.8900240659713745 |
| keywords[0].display_name | Apixaban |
| keywords[1].id | https://openalex.org/keywords/dabigatran |
| keywords[1].score | 0.8424474000930786 |
| keywords[1].display_name | Dabigatran |
| keywords[2].id | https://openalex.org/keywords/rivaroxaban |
| keywords[2].score | 0.8296358585357666 |
| keywords[2].display_name | Rivaroxaban |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.8181043863296509 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[4].score | 0.5364568829536438 |
| keywords[4].display_name | Intensive care medicine |
| keywords[5].id | https://openalex.org/keywords/warfarin |
| keywords[5].score | 0.4831813871860504 |
| keywords[5].display_name | Warfarin |
| keywords[6].id | https://openalex.org/keywords/polypharmacy |
| keywords[6].score | 0.4273143410682678 |
| keywords[6].display_name | Polypharmacy |
| keywords[7].id | https://openalex.org/keywords/psychological-intervention |
| keywords[7].score | 0.4142628014087677 |
| keywords[7].display_name | Psychological intervention |
| keywords[8].id | https://openalex.org/keywords/emergency-medicine |
| keywords[8].score | 0.34862154722213745 |
| keywords[8].display_name | Emergency medicine |
| keywords[9].id | https://openalex.org/keywords/atrial-fibrillation |
| keywords[9].score | 0.3006132245063782 |
| keywords[9].display_name | Atrial fibrillation |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.2486635446548462 |
| keywords[10].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1136/ejhpharm-2018-eahpconf.108 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S4363605422 |
| locations[0].source.issn | |
| locations[0].source.type | conference |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Section 4: Clinical pharmacy services |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | proceedings-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Section 4: Clinical pharmacy services |
| locations[0].landing_page_url | https://doi.org/10.1136/ejhpharm-2018-eahpconf.108 |
| locations[1].id | pmh:oai:open-archive.highwire.org:ejhpharm:25/Suppl_1/A49-a |
| locations[1].is_oa | False |
| locations[1].source | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | TEXT |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | http://ejhp.bmj.com/cgi/content/short/25/Suppl_1/A49-a |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:7535373 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Eur J Hosp Pharm |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7535373 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5101723149 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9817-8066 |
| authorships[0].author.display_name | Konstantinos Ioannidis |
| authorships[0].countries | GR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210122009 |
| authorships[0].affiliations[0].raw_affiliation_string | Hygeia Hospital, Clinical Pharmacology, Athens, Greece |
| authorships[0].institutions[0].id | https://openalex.org/I4210122009 |
| authorships[0].institutions[0].ror | https://ror.org/03qv5tx95 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210122009 |
| authorships[0].institutions[0].country_code | GR |
| authorships[0].institutions[0].display_name | Hygeia Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | K Ioannidis |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Hygeia Hospital, Clinical Pharmacology, Athens, Greece |
| authorships[1].author.id | https://openalex.org/A5020636760 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | I Scarlatinis |
| authorships[1].countries | GR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210122009 |
| authorships[1].affiliations[0].raw_affiliation_string | Hygeia Hospital, Clinical Pharmacology, Athens, Greece |
| authorships[1].institutions[0].id | https://openalex.org/I4210122009 |
| authorships[1].institutions[0].ror | https://ror.org/03qv5tx95 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210122009 |
| authorships[1].institutions[0].country_code | GR |
| authorships[1].institutions[0].display_name | Hygeia Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | I Scarlatinis |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Hygeia Hospital, Clinical Pharmacology, Athens, Greece |
| authorships[2].author.id | https://openalex.org/A5072785057 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0433-0931 |
| authorships[2].author.display_name | Apostolos Papachristos |
| authorships[2].countries | GR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210122009 |
| authorships[2].affiliations[0].raw_affiliation_string | Hygeia Hospital, Clinical Pharmacology, Athens, Greece |
| authorships[2].institutions[0].id | https://openalex.org/I4210122009 |
| authorships[2].institutions[0].ror | https://ror.org/03qv5tx95 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210122009 |
| authorships[2].institutions[0].country_code | GR |
| authorships[2].institutions[0].display_name | Hygeia Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | A Papachristos |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Hygeia Hospital, Clinical Pharmacology, Athens, Greece |
| authorships[3].author.id | https://openalex.org/A5060387493 |
| authorships[3].author.orcid | https://orcid.org/0009-0001-1900-9924 |
| authorships[3].author.display_name | Xenia Madia |
| authorships[3].affiliations[0].raw_affiliation_string | Private Pharmacy, Athens, Greece |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | X Madia |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Private Pharmacy, Athens, Greece |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7535373 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 4CPS-017 Misuse of novel oral anticoagulants in hospital settings |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10496 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9125999808311462 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2717 |
| primary_topic.subfield.display_name | Geriatrics and Gerontology |
| primary_topic.display_name | Pharmaceutical Practices and Patient Outcomes |
| related_works | https://openalex.org/W2093259736, https://openalex.org/W2543625995, https://openalex.org/W2083901189, https://openalex.org/W2327960115, https://openalex.org/W1975219299, https://openalex.org/W1436836526, https://openalex.org/W2046188252, https://openalex.org/W4205842753, https://openalex.org/W4292463656, https://openalex.org/W2523933248 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2018 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:7535373 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | Eur J Hosp Pharm |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7535373 |
| primary_location.id | doi:10.1136/ejhpharm-2018-eahpconf.108 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S4363605422 |
| primary_location.source.issn | |
| primary_location.source.type | conference |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Section 4: Clinical pharmacy services |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | proceedings-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Section 4: Clinical pharmacy services |
| primary_location.landing_page_url | https://doi.org/10.1136/ejhpharm-2018-eahpconf.108 |
| publication_date | 2018-03-01 |
| publication_year | 2018 |
| referenced_works_count | 0 |
| abstract_inverted_index.1 | 99 |
| abstract_inverted_index.A | 88 |
| abstract_inverted_index.a | 23, 81, 94, 158, 298, 307, 336, 341 |
| abstract_inverted_index.28 | 164 |
| abstract_inverted_index.31 | 103 |
| abstract_inverted_index.37 | 216 |
| abstract_inverted_index.42 | 155 |
| abstract_inverted_index.76 | 201 |
| abstract_inverted_index.In | 1 |
| abstract_inverted_index.No | 221, 344 |
| abstract_inverted_index.an | 36 |
| abstract_inverted_index.as | 137, 259, 285, 340 |
| abstract_inverted_index.at | 93 |
| abstract_inverted_index.be | 196 |
| abstract_inverted_index.by | 205, 232 |
| abstract_inverted_index.if | 241 |
| abstract_inverted_index.in | 26, 52, 80, 109, 281, 295, 306 |
| abstract_inverted_index.is | 50, 70, 274 |
| abstract_inverted_index.of | 8, 30, 47, 66, 148, 153, 200, 208, 215, 301, 335, 346 |
| abstract_inverted_index.on | 174, 255, 277 |
| abstract_inverted_index.or | 18, 288 |
| abstract_inverted_index.so | 136 |
| abstract_inverted_index.to | 40, 54, 71, 102, 113, 138, 168, 179, 185, 195, 227, 239, 269, 317 |
| abstract_inverted_index.(13 | 199 |
| abstract_inverted_index.(28 | 207 |
| abstract_inverted_index.257 | 209 |
| abstract_inverted_index.370 | 146 |
| abstract_inverted_index.The | 64, 290, 315 |
| abstract_inverted_index.Xa, | 20 |
| abstract_inverted_index.age | 116 |
| abstract_inverted_index.aim | 65 |
| abstract_inverted_index.all | 127 |
| abstract_inverted_index.and | 42, 58, 86, 117, 182, 212, 251, 264, 322 |
| abstract_inverted_index.are | 230, 236, 244 |
| abstract_inverted_index.be, | 228 |
| abstract_inverted_index.due | 268 |
| abstract_inverted_index.few | 4 |
| abstract_inverted_index.has | 21 |
| abstract_inverted_index.how | 223 |
| abstract_inverted_index.not | 245 |
| abstract_inverted_index.our | 296 |
| abstract_inverted_index.six | 183 |
| abstract_inverted_index.the | 2, 6, 27, 44, 67, 120, 123, 191, 249, 311, 332 |
| abstract_inverted_index.two | 73 |
| abstract_inverted_index.use | 46 |
| abstract_inverted_index.was | 91, 190, 328 |
| abstract_inverted_index.way | 308 |
| abstract_inverted_index.(one | 214 |
| abstract_inverted_index.2016 | 101 |
| abstract_inverted_index.Both | 248 |
| abstract_inverted_index.Data | 133 |
| abstract_inverted_index.NOAC | 194 |
| abstract_inverted_index.age, | 262 |
| abstract_inverted_index.from | 98 |
| abstract_inverted_index.into | 326 |
| abstract_inverted_index.more | 237 |
| abstract_inverted_index.most | 192 |
| abstract_inverted_index.oral | 11 |
| abstract_inverted_index.past | 3 |
| abstract_inverted_index.risk | 253 |
| abstract_inverted_index.seem | 226 |
| abstract_inverted_index.such | 258, 284, 339 |
| abstract_inverted_index.take | 318 |
| abstract_inverted_index.that | 309 |
| abstract_inverted_index.they | 34, 229 |
| abstract_inverted_index.were | 107, 131, 134, 151, 166 |
| abstract_inverted_index.with | 331 |
| abstract_inverted_index.(19%) | 178 |
| abstract_inverted_index.2016. | 105 |
| abstract_inverted_index.Among | 161 |
| abstract_inverted_index.NOACs | 106, 130, 225, 305 |
| abstract_inverted_index.along | 330 |
| abstract_inverted_index.avoid | 59 |
| abstract_inverted_index.based | 173 |
| abstract_inverted_index.cases | 128, 147 |
| abstract_inverted_index.doses | 111 |
| abstract_inverted_index.eight | 177 |
| abstract_inverted_index.label | 313 |
| abstract_inverted_index.novel | 10 |
| abstract_inverted_index.order | 53 |
| abstract_inverted_index.ratio | 280 |
| abstract_inverted_index.renal | 175, 260 |
| abstract_inverted_index.risks | 234 |
| abstract_inverted_index.study | 69, 90, 121, 292 |
| abstract_inverted_index.that, | 294 |
| abstract_inverted_index.their | 56, 270, 278 |
| abstract_inverted_index.there | 273 |
| abstract_inverted_index.these | 48, 162, 242 |
| abstract_inverted_index.three | 9 |
| abstract_inverted_index.usage | 79 |
| abstract_inverted_index.used. | 247 |
| abstract_inverted_index.where | 129 |
| abstract_inverted_index.which | 14, 235 |
| abstract_inverted_index.10.9%) | 211 |
| abstract_inverted_index.2.7%). | 218 |
| abstract_inverted_index.During | 119 |
| abstract_inverted_index.active | 187 |
| abstract_inverted_index.agents | 49, 243 |
| abstract_inverted_index.amount | 300 |
| abstract_inverted_index.cases, | 202, 210, 283 |
| abstract_inverted_index.cases. | 217 |
| abstract_inverted_index.change | 25 |
| abstract_inverted_index.depend | 254 |
| abstract_inverted_index.dosage | 172 |
| abstract_inverted_index.effect | 57 |
| abstract_inverted_index.error. | 160 |
| abstract_inverted_index.factor | 19 |
| abstract_inverted_index.happen | 240 |
| abstract_inverted_index.likely | 238 |
| abstract_inverted_index.matter | 222 |
| abstract_inverted_index.option | 39 |
| abstract_inverted_index.recent | 271 |
| abstract_inverted_index.reveal | 139 |
| abstract_inverted_index.showed | 293 |
| abstract_inverted_index.target | 16 |
| abstract_inverted_index.weight | 263 |
| abstract_inverted_index.which, | 154 |
| abstract_inverted_index.years, | 5 |
| abstract_inverted_index.(11.4%) | 156, 303 |
| abstract_inverted_index.(14.3%) | 184 |
| abstract_inverted_index.(66.7%) | 165 |
| abstract_inverted_index.17.1%), | 203 |
| abstract_inverted_index.General | 96 |
| abstract_inverted_index.January | 100 |
| abstract_inverted_index.Private | 95 |
| abstract_inverted_index.account | 327 |
| abstract_inverted_index.adverse | 60 |
| abstract_inverted_index.brought | 22 |
| abstract_inverted_index.cancer, | 286 |
| abstract_inverted_index.cancer. | 188 |
| abstract_inverted_index.errors. | 142 |
| abstract_inverted_index.events. | 61 |
| abstract_inverted_index.expert, | 338 |
| abstract_inverted_index.history | 321 |
| abstract_inverted_index.medical | 320 |
| abstract_inverted_index.obesity | 287 |
| abstract_inverted_index.patient | 256 |
| abstract_inverted_index.period, | 122 |
| abstract_inverted_index.present | 68, 291 |
| abstract_inverted_index.private | 82 |
| abstract_inverted_index.product | 312 |
| abstract_inverted_index.related | 167 |
| abstract_inverted_index.several | 233 |
| abstract_inverted_index.special | 282 |
| abstract_inverted_index.(NOACs), | 13 |
| abstract_inverted_index.Although | 33 |
| abstract_inverted_index.Apixaban | 189 |
| abstract_inverted_index.December | 104 |
| abstract_inverted_index.Hospital | 97 |
| abstract_inverted_index.NOACs’ | 78, 149, 171, 323 |
| abstract_inverted_index.Totally, | 145 |
| abstract_inverted_index.analysed | 135 |
| abstract_inverted_index.bleeding | 252 |
| abstract_inverted_index.clinical | 28, 74, 124, 342 |
| abstract_inverted_index.conflict | 345 |
| abstract_inverted_index.directly | 15 |
| abstract_inverted_index.efficacy | 250 |
| abstract_inverted_index.followed | 204 |
| abstract_inverted_index.frequent | 193 |
| abstract_inverted_index.heparin, | 43 |
| abstract_inverted_index.included | 157 |
| abstract_inverted_index.interest | 347 |
| abstract_inverted_index.maximise | 55 |
| abstract_inverted_index.patients | 302 |
| abstract_inverted_index.practice | 29 |
| abstract_inverted_index.received | 304 |
| abstract_inverted_index.therapy. | 32 |
| abstract_inverted_index.thrombin | 17 |
| abstract_inverted_index.warfarin | 41 |
| abstract_inverted_index.whereas, | 267 |
| abstract_inverted_index.according | 112 |
| abstract_inverted_index.conducted | 92 |
| abstract_inverted_index.different | 110 |
| abstract_inverted_index.drug-drug | 180 |
| abstract_inverted_index.essential | 51 |
| abstract_inverted_index.function, | 176, 261 |
| abstract_inverted_index.hospital, | 297 |
| abstract_inverted_index.hospital. | 83 |
| abstract_inverted_index.mistakes, | 163 |
| abstract_inverted_index.necessity | 316 |
| abstract_inverted_index.potential | 140, 333 |
| abstract_inverted_index.recorded, | 152 |
| abstract_inverted_index.regarding | 77 |
| abstract_inverted_index.attractive | 37 |
| abstract_inverted_index.calculated | 170 |
| abstract_inverted_index.childhood. | 289 |
| abstract_inverted_index.concurrent | 186 |
| abstract_inverted_index.constitute | 35 |
| abstract_inverted_index.dabigatran | 213 |
| abstract_inverted_index.documented | 126 |
| abstract_inverted_index.experience | 276 |
| abstract_inverted_index.medication | 141, 159 |
| abstract_inverted_index.remarkable | 24 |
| abstract_inverted_index.variables, | 257 |
| abstract_inverted_index.accompanied | 231 |
| abstract_inverted_index.alternative | 38 |
| abstract_inverted_index.appropriate | 45 |
| abstract_inverted_index.bodyweight, | 115 |
| abstract_inverted_index.concomitant | 265 |
| abstract_inverted_index.contradicts | 310 |
| abstract_inverted_index.development | 7 |
| abstract_inverted_index.erroneously | 169, 197 |
| abstract_inverted_index.guidelines. | 314 |
| abstract_inverted_index.indication, | 114 |
| abstract_inverted_index.investigate | 72 |
| abstract_inverted_index.medication, | 266 |
| abstract_inverted_index.patients’ | 319 |
| abstract_inverted_index.pharmacist. | 343 |
| abstract_inverted_index.pharmacists | 125 |
| abstract_inverted_index.prescribed. | 132 |
| abstract_inverted_index.prospective | 89 |
| abstract_inverted_index.rivaroxaban | 206 |
| abstract_inverted_index.significant | 299 |
| abstract_inverted_index.</sec> | 62, 84, 143, 219, 348 |
| abstract_inverted_index.administered | 108, 198 |
| abstract_inverted_index.advantageous | 224 |
| abstract_inverted_index.contribution | 334 |
| abstract_inverted_index.highlighted, | 329 |
| abstract_inverted_index.insufficient | 275 |
| abstract_inverted_index.interactions | 181 |
| abstract_inverted_index.appropriately | 246 |
| abstract_inverted_index.drug-handling | 337 |
| abstract_inverted_index.interventions | 76 |
| abstract_inverted_index.administration | 150 |
| abstract_inverted_index.anticoagulants | 12 |
| abstract_inverted_index.authorisation, | 272 |
| abstract_inverted_index.comorbidities. | 118 |
| abstract_inverted_index.pharmacists’ | 75 |
| abstract_inverted_index.anticoagulation | 31 |
| abstract_inverted_index.benefit-to-risk | 279 |
| abstract_inverted_index.characteristics | 325 |
| abstract_inverted_index.pharmacological | 324 |
| abstract_inverted_index.methods</st> | 87 |
| abstract_inverted_index.<sec><st>Material | 85 |
| abstract_inverted_index.<sec><st>Purpose</st> | 63 |
| abstract_inverted_index.<sec><st>Results</st> | 144 |
| abstract_inverted_index.<sec><st>Background</st> | 0 |
| abstract_inverted_index.<sec><st>Conclusion</st> | 220 |
| cited_by_percentile_year.max | 94 |
| cited_by_percentile_year.min | 90 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 4 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.95121951 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |